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Abstract
Objectives: To study the safety and efficacy of AngioVac for left‐sided transcatheter
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vacuum‐assisted mass extraction (TVME).
Background: The AngioVac system is approved for right‐sided TVME and has
emerged as an effective and safe alternative for open surgical treatment. The use of
the AngioVac device for aspiration of left‐sided TVME has been limited.
Methods: Consecutive patients from two Michigan centers who underwent
left‐sided TVME were included. Data on patient demographics, procedural
information, in‐hospital and follow‐up events were collected through electronic
medical records review. Technical success was defined as aspirating of 70%–100%
of the material.
Results: Ten patients (mean age 58.3 [±17.3] years, 50% male) were included.
Indications for TMVE were in large for recurrent embolic events. All patients
underwent bilateral cerebro‐embolic protection using the Sentinel device. The total
mean procedure time was 192.5 (±47.5) min of which the meantime for active
aspiration (bypass time) was 9.3 (±4.2) min. The circuit configuration was:
arteriovenous (AV) in four cases and arterioarterial (AA) in six cases. Successful
aspiration was achieved in 80% of cases. No complications were reported
(range follow‐up 1–16 months).
Conclusions: Our small case series demonstrates the feasibility and safety of the
AngioVac system in left‐sided mass extraction. Larger trials are needed to further
demonstrate its effectiveness and safety and potentially apply for on‐label use.
KEYWORDS

CATT—catheterization, ENDO—endocarditis, THRO—thrombectomy, transseptal
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| INTRODUCTION

Drug Administration‐approved TVME device capable of removing
intravascular thrombi or vegetations without the need of thrombo-

Transcatheter vacuum‐assisted mass extraction (TVME) has emerged

lytics. Although the AngioVac device was originally designed and

as an effective and safe alternative to open surgical thrombectomy,

approved for removal of right‐sided fresh thrombus, its use has

especially in high‐risk patients with right‐sided thrombosis or

expanded for retrieval of a variety of intravascular materials such as

vegetation.1 The AngioVac system (AngioDynamics) is a Food and

right‐sided infective endocarditis vegetations, tumor thrombus,

Catheter Cardiovasc Interv. 2022;1–8.
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catheter‐ or device‐related thrombus, and intravascular or intracardiac
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PROCEDURE DETAILS

masses.2,3 The use of the AngioVac device for aspiration of left‐sided
intravascular materials has been limited.4 Moreover, the AngioVac

All patients underwent the procedure using the third generation 180°

system is designed to be a venovenous filtration device and is rarely

24 Fr AngioVac catheter combined with a bypass circuit and a re‐

been used as an arterioarterial (AA) filtration device. Hereby we report a

infusion cannula. Two access sites are required for aspiration and

two‐center experience with the AngioVac system for left‐sided mass

reperfusion. The extracorporeal bypass circuit consists of an outflow

extraction and its occasional use as an AA filtration device.

line (i.e., connected to the AngioVac cannula), a centrifugal pump, a
filter, and an inflow line (i.e., connected to the return cannula)
(Figure 1). After the cannula is connected, the centrifugal pump is
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activated creating a one‐way flow providing suction at the cannula tip
and the aspirated material will be filtered through the filter of the

Consecutive patients (February 2020 till November 2021) with left‐

pump. The circuit then reinfuses the filtered blood back into the body

sided TVME procedures with the AngioVac device at Henry Ford

through the reperfusion cannula to minimize blood loss.

Hospital (Detroit, Michigan) and Sparrow Hospital (Lansing, Michigan)

Typically, for right‐sided lesions, both cannulas are placed in the

were included in this study. Data were collected using the electronic

venous system (veno‐venous circuit). For left‐sided lesions, two

medical record. Henry Ford institutional review board approval was

circuits can be utilized; arteriovenous (AV) and AA circuits (Figure 1

obtained for data collection for this case series and all patients signed

for the AA configuration).

informed consent specifically for this procedure. We excluded

For stroke prevention, all patients underwent cerebral embolic

patients who underwent only right‐sided aspiration procedures and

protection (aided with preprocedural computed tomography planning)

patients who underwent TVME with other thrombectomy devices.

with the Sentinel device (for the right innominate and the left carotid

Data collected included patient demographics, procedural informa-

arteries); some with bilateral protection (for the left subclavian artery

tion, and in‐hospital events. Removal of thrombus or mass was

in addition to the right innominate and the left carotid arteries).

reported as 0%, 1%–50%, 50%–70%, or 70%–100%, as determined
by reviewing the TEE images obtained during the procedure.
Consistent with prior literature, aspirating 70%–100% of the material
was determined to be the definition of technical success.5,6 The
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definition of procedural success is technical success without any
complications (including death, myocardial infarction, systemic

Traditionally, after transseptal access is obtained, the AngioVac

embolism, stroke, vascular complications, and major bleeding). The

system (which comes with a dilator) is advanced into the left atrium

clinical outcome was assessed at the time of case series generation

over a stiff wire. Frequently, this presents a challenge (due to the

and the follow‐up time length varied by patient and is mentioned in

large size of the device); especially in a thickened septum. In addition

detail in Table 2.

to tracking difficulty, we find that removing the dilator and

F I G U R E 1 Schematic of the AngioVac
circuit configuration for left‐sided
aspiration [Color figure can be viewed at
wileyonlinelibrary.com]
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TABLE 1
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aortic arch (n = 3). The total mean procedure time was 192.5 (±47.5)

Baseline characteristics of included patients

Variable

Value

Age (years), mean (±SD)

58.3 (±17.3)

min of which the meantime for active aspiration (bypass time) was 9.3
(±4.2) min. The circuit configuration was AV in four cases and AA in six
cases. The main access site for the aspiration cannula initial entry point

Male, N (%)

5 (50%)

was transseptal in 7 (70%) cases, transcaval in 2 cases, and transfemoral

Hypertension, N (%)

5 (50%)

in 1 patient. Bilateral cerebroembolic protection was used bilaterally in

Diabetes mellitus, type 2, N (%)

3 (30%)

100% of patients (all with bilateral Sentinel devices except for two

Left ventricular dysfunction, N (%)

1 (10%)

Active tobacco abuse, N (%)

3 (30%)

the material) was achieved in 8 (80%) of cases (Figure 2, Videos 1–3).

Alcohol/polysubstance abuse, N (%)

3 (30%)

No complications (death, myocardial infarction, systemic embolism,

Atrial fibrillation, N (%)

3 (30%)

stroke, vascular complications, and major bleeding) were noted,

Hypercoagulable state, N (%)

1 (10%)

Taking anticoagulation, N (%)

2 (20%)

End‐stage renal disease, N (%)

1 (10%)

Active intravenous drug use, N (%)

1 (10%)

patients with left subclavian occlusion balloon).
A successful aspiration (defined as aspirating more than 70% of

acutely or at follow up (range is 1–16 months).
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Our case series demonstrates feasibility and safety of the AngioVac
system in aspiration of left‐sided masses. Several types of masses
or lesions can be encountered on the left side that are worth
assembling the AngioVac device for use leads to substantial blood

mentioning.

loss. An alternative approach, which saves blood loss and makes

The first of these is for left atrial (LA) or LAA thrombi. LA/LAA

tracking a lot easier, is the balloon‐assisted tracking. The technique is

thrombi may occur in up to 6.3% of AF patients on anticoagulation

as follows: an 8 or 10 mm (40 or 60 mm length) Armada (or similar

and up to 5.5% of patients who are undergoing cardioversion.7 The

brands) balloon is preloaded inside the AngioVac suction catheter

mainstay of treatment for this is anticoagulation, however, some

over a wire. The balloon is positioned at the tip of the device and

patients may not tolerate a prolonged therapeutic trial of antic-

inflated outside of the body. The balloon now acts like a dilator and

oagulation. These patients may be candidates for LA appendage

the whole assembly can be advanced as one unit over the wire until it

occlusion, however, the presence of a thrombus would normally

reaches the septum. Next, the balloon is deflated and is used to

preclude them from consideration. Moreover, despite therapeutic

balloon the septum and while the balloon is up, the AngioVac can be

treatment with anticoagulation, some patients will have persistent

advanced into the left atrium easily (Video 1).

thrombus. In a published paper in 2019, the prevalence of LAA
thrombus was 8% in patients with AF. Even with the prescription of
adequate anticoagulation regimen, the thrombus resolution rate was

5
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only 79%.8 Treating these patients with left‐sided AngioVac‐assisted
aspiration might prove to be a useful and successful strategy.

A total of 10 patients (8 at Henry Ford Hospital and 2 at Sparrow

Endocarditis is another area where vacuum aspiration may have

Hospital) received left‐sided TVME and their baseline demographics

utility. The experience with AngioVac in the management of

are reviewed in Table 1. The mean age of our patients was 58.3

endocarditis is limited mainly to those patients with tricuspid valve

(±17.3) years and 50% were male. Overall, 50% of patients had

vegetations. A similar framework may also be applied to the mitral

hypertension, and 30% were diabetics, 30% were active smokers,

valve. Current rates of morbidity and mortality of mitral valve surgery

30% had a history of atrial fibrillation (AF) and 20% were taking

for endocarditis are 6%–25%.9 However, some patients referred for

anticoagulation.

mitral valve replacement for endocarditis may have other medical

The patients detailed history and presentations are found in

comorbidities which make them prohibitive surgical candidates. Many

Table 2. The indications for doing the TVME included: acute recurrent

times these vegetations may be bulky and can lead to disseminated

cerebrovascular accidents (n = 3), acute limb ischemia (n = 1), need for

infection and death if source control is not obtained. Our experience

left atrial appendage (LAA) closure with persistent thrombus despite

demonstrated a marked reduction in the size of these lesions, which

medical therapy (n = 2), multiple systemic emboli involving the brain,

may subsequently allow sterilization through antibiotic therapy.

kidneys and the spleen (n = 1), unclearing blood cultures with severe

Moreover, debulking of this vegetation might prove useful in

fevers and chills for weeks (n = 1), large mobile thrombus in the left

preventing cerebrovascular events that might be fatal in this

atrium (n = 1), and possible embolic coronary event (n = 1). The

patient population.

location of the aspirated thrombi was as follows: left atrium (n = 4)

Floating aortic arch thrombus is another potentially life‐

(one in the body of the left atrium and one on the mitral valve ring and

threatening condition for which thrombus evacuation may prove

two on the mitral valve leaflets), LAA (n = 2), left ventricle (n = 1), and

useful. Left untreated this condition may be a cause of recurrent

55‐year‐old female with active
smoking, htpothyroidisim.
Presented with stroke, acute
limb ischemia

86‐year‐old female with history of
severe aortic stenosis s/p
transcatheter aortic valve
replacement, atrial fibrillation
with chronic anemia and
intolerance of anticoagulation,
hypertension. The patient is in
need of a watchman procedure

4

Transcaval

Transseptal

AV
− Aspiration:
AngioVac in the
aorta via
transcaval
− Return: 17 Fr
cannula in left
femoral vein
AA
− Aspiration:
AngioVac in the
left atrial
appendage
− Return: 17 Fr
cannula in right
femoral artery

300/12 min
(two runs)

150/6 min
(one run)

Aortic arch
thrombus

Persistent left
atrial
appendage
thrombus

Transseptal

AV
− Aspiration:
AngioVac in the
left ventricle
− Return: 19 Fr
cannula in left
femoral vein

195/7 min (for
the LV
part only)

Acute thrombus
36‐year‐old male with alcohol
in the left
abuse, recent diagnosis of
ventricle/left
nonischemic cardiomyopathy
ventricular
(ejection fraction of 19%).
outflow tract
Presented with acute hypoxic
respiratory failure and found to
have a large mobile right atrial
thrombus, multiple pulmonary
emboli and acute thrombus in
the left ventricle/left ventricular
outflow tract with possible
embolic coronary event causing
acute coronary syndrome

2
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Transseptal

AV
− Aspiration:
AngioVac in the
left atrium
− Return: 19 Fr
cannula in left
femoral vein

180/10 min
(multiple
runs)

65‐year‐old female with history of Large left atrial
thrombus
asthma, obstructive sleep apnea
on CPAP, atrial fibrillation, mitral
valve regurgitation s/p surgical
repair. Came with acute stroke
and diagnosed with heparin‐
induced thrombocytopenia and
found large left atrial thrombus

Main access
approach

Circuit configuration
(AV, VA, VV, or AA)

1

Total
AngioVac
procedure
time/
bypass time

Summary table of detailed patients’ information

Patient details/clinical presentation Location

TABLE 2

Bilateral

Bilateral

Bilateral

Bilateral

Sentinel use?

Yes, 100% aspirated

No complications. Alive
a well at 4 months
follow up

No complications. Alive
and well at 4 months
follow up

No complications. Alive
and well at 5 months
follow up

− Yes for the left
ventricular
outflow tract
part (100%
aspirated)
− No, for the left
ventricular
thrombus part
(20% aspiration)

Yes, 70% aspirated

No complications. Alive
and well at 7 months
follow up

Clinical outcome

No. 0% aspirated
(chronic thrombus
adhered to
the wall)

Success/% aspirated

4
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60‐year‐old male, history of recent
strokes (x2), hypertension, atrial
fibrillation on anticoagulation
with warfarin, sick sinus
syndrome s/p permeant
pacemaker, mitral valve repair
with a surgical ring. Presented
multiple strokes, work up noted
a mass on the posterior aspect
of his mitral valve ring with
moderate to severe mitral
regurgitation

Transseptal

Transcaval

AA
− Aspiration:
AngioVac in the
left atrium
− Return: 15 Fr
cannula in left
femoral artery

AA
− Aspiration:
AngioVac in the
ascending aorta
via transcaval
access
− Return: 15 Fr
cannula in right
femoral artery

165/5 min
(one run)

210/7 min
(one run)

Posterior aspect
of mitral
valve
ring with

40‐year‐old male, history of
obstructive hypertrophic
cardiomyopathy, hypertension,
diabetes mellitus type II on
insulin. Presented with acute
COVID pneumonia and multiple
systemic emboli (LMCA stroke,
splenic and renal infarction)
found to have an aortic arch
thrombus

7

Aortic arch
thrombus

Main access
approach

Transseptal

Circuit configuration
(AV, VA, VV, or AA)

AA
− Aspiration:
AngioVac in the
left atrial
appendage
− Return: 15 Fr
cannula in left
femoral artery

Total
AngioVac
procedure
time/
bypass time

160/10 min
(two runs)

77‐year‐old female with history of Persistent left
atrial
atrial fibrillation on Eliquis,
appendage
gastrointesntinal bleeding,
thrombus
severe aortic stenosis s/p
surgical valve replacement with
bioprosthetic valve,
hypertension. The patient is in
need of a watchman but unable
to dissolve Left atrial appendage
thrombus medically

but unable to dissolve left atrial
appendage thrombus medically

6
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(Continued)

Patient details/clinical presentation Location

TABLE 2

Bilateral

Bilateral

Bilateral

Sentinel use?

Yes. 90% removal of
the thrombus

Yes, 70% aspirated

No (only 50%
aspiration)

Success/% aspirated

(Continues)

No complications. Alive
and well at 1 month
follow up, no
recurrent events

No complications. Alive
and well at 1 month.
Pathology confirmed
the diagnosis of the
mass as a thrombus

No complications. Alive
and well at 1 month

Clinical outcome

QINTAR
ET AL.
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(Continued)

Transseptal

Success/% aspirated

Sentinel in the right
brachiocephalic and
the left carotid and
an inflated balloon in
the left subclavian

Bilateral

Yes. 100% of the
mobile mass was
aspirated
successfully

Yes. 90% of the
vegetation was
aspirated

Right‐sided Sentinel with Yes (80% aspirated)
left subclavian 8.0
Armada occlusion
balloon

Sentinel use?

Abbreviations: AA, arterioarterial; AV, arteriovenous; CPAP, continuous positive airway pressure; LMCA, left main coronary artery; VA, venoarterial; VV, venovenous.

120/7 min

AA
− Aspiration:
AngioVac in the
left atrium
− Return: 16 Fr
cannula in right
femoral artery

10 43‐year‐old male with history of
end‐stage kidney disease on
dialysis with history of infective
endocarditis that was treated
conservatively now presenting
with a mass on his mitral valve
without signs of systemic
infection

Large mobile
mass on
posterior
leaflet of
mitral valve

Transseptal

AA
− Aspiration:
AngioVac in the
left atrium
− Return: 16 Fr
cannula in left
femoral artery

180/10 min
Mitral valve
vegetation on
the posterior
leaflet

9

31‐year‐old male with history of
active intravenous drug use,
hepatitis C who presented with
septic shock, positive
nonclearing blood cultures

Left femoral artery
(10.1 × 10.6 mm)

AV
− Aspiration:
AngioVac in the
ascending aorta
via left femoral
artery
− Return: 19 Fr
cannula in right
femoral vein

Main access
approach

Circuit configuration
(AV, VA, VV, or AA)

180/18 min
Aortic arch
48‐year‐old male with history of
(three
thrombus and
active smoking, peripheral
different
infra‐renal
arterial disease, diabetes mellitus
runs)
abdominal
type II, polysubstance abuse
aortic
(opiate, cocaine) who presented
thrombus
with acute LMCA stroke
(presented 24 h later)

Total
AngioVac
procedure
time/
bypass time
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Patient details/clinical presentation Location

TABLE 2

No complications. Alive
and well at 2 months
follow up

No complications, alive
and well at 3 months
follow up

No complications. Alive
and well at 16
months post op

Clinical outcome
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F I G U R E 2 Annonated echocardiographic figures of a case example: (A) Preprocedure echocardiogram showing a large mitral valve
vegetation. (B) Intraprocedural echocardiogram showing the AngioVac cannula engaged in the vegetation. (C) Final echocardiogram
postprocedure showing no residual vegetation. [Color figure can be viewed at wileyonlinelibrary.com]

cerebral vascular accidents. This condition may be stabilized with

our small case series, we have demonstrated its safety; the use of this

anticoagulation, but in a single center experience, the majority of

device is off‐label for left‐sided lesions and is not without risk. Its use

cases underwent open thrombectomy. 10 Accessing the ascending

should be taken on a case‐by‐case basis and with careful planning.

aorta may prove challenging with the AngioVac system given the
size of the arterial cannula that is required. Transcaval access is a

CONFLIC TS OF I NTERES T

solution to this in those patients who may not have peripheral

Dr. Wang is a consultant for Boston Scientific, Abbott Vascular,

access (Videos 2–4).

and Materialise. Drs. Frisoli and Eng are proctors for Edwards

When treating left‐sided masses one must think about the circuit

LifeSciences. Dr. Brian P. O'Neill is a consultant to Edwards

configuration. Since most of its use is for right‐sided lesions, the

Lifescience and Abbott and receives research funding from

typical circuit for the AngioVac system is venovenous circuit.

Edwards Lifesciences. The remaining authors have no relevant

However, all of our patients underwent aspiration of left‐sided

relationships to disclose.

lesions and thus the aspiration cannula is on the arterial side (whether
directly placed into the arterial system or indirectly into the left
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Our initial experience demonstrates the AngioVac system can be
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considered for patients with left‐sided lesions who may be at
elevated risk of a surgical approach. The novel cannula design with a
self‐expanding funnel tip and ability to flex and unflex; allows for safe
navigation intravascularly and inside cardiac chambers. Although in
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